Too much or never enough: a response to 
                   by unknown
COMMENTARY Open Access
Too much or never enough: a response to
Treatment of opioid disorders in Canada:
looking at the ‘other epidemic’
Joseph K. Eibl1, Kristen A. Morin-Taus1 and David C. Marsh1,2*
Abstract
Prescription opioid (PO) misuse is a major health concern across North America, and it is the primary cause of
preventable death for the 18–35 year old demographic. Medication assisted therapy including methadone and
buprenorphine, is the standard of care for patients with opioid-dependence. Moreover, both of these medications
are recognized as essential medicines by World Health Organization. In Ontario Canada, the availability of
medication assisted therapy has expanded substantially, with almost a ten-fold increase number of patients
accessing methadone in Ontario in the past decade. In their manuscript, Fischer et. al. (2016), present a view that
expansion of opioid maintenance therapy (OMT) has outpaced true patient need and alternate strategies should be
considered as first-line treatments. Here, we present a countering perspective-that medication assisted therapy,
along with other harm reduction strategies, should be widely available to all opioid-dependent people as first-line
treatments.
Background
Prescription opioid (PO) misuse is a major health con-
cern across North America. Fueled by liberal PO pre-
scribing during the late 1990’s and 2000’s, Ontario is
often cited as a region suffering from a public health cri-
sis due to PO-dependence [7, 11, 14]. Today, opioid-
related overdose is the number one cause of death for
18–35 year olds in Ontario [12], and this trend holds
true for Canada and the US [20]. Sadly, opioid-overdose
deaths are far more likely to occur following abstinence-
based treatment programs; and the reason is all too
often relapse during a time of increased opioid sensitiv-
ity which follows detox [5]. In an effort to address the
PO epidemic, some provinces in Canada have dramatic-
ally expanded access to medication assisted therapy, in-
cluding the province of Ontario.
The evidence to support the efficacy of medication
assisted treatment (e.g., methadone and buprenorphine)
is well established for heroin-using patients [3], and due
to the pharmacological similarities of prescription
opioids (including oxycodone) methadone and bupre-
norphine have demonstrated efficacy for prescription
opioid users as well [4]. However, Fisher et. al., (2016)
also question the generalizability of studies conducted in
a heroin-using population to the prescription opioid-
dependent population.
Recently, the question has been raised, when is there
too much medication assisted therapy? Fischer et. al.,
(2016) present a view that expansion of opioid mainten-
ance therapy (OMT) has outpaced true patient need for
treatment in the province of Ontario, Canada. Further,
the authors imply that economic incentives surrounding
delivery of methadone have ‘unduly influenced the ex-
pansion of OMT in Ontario’. Finally, the authors argue
towards a continuum-of-care which focuses on alterna-
tives to maintenance therapy citing taper, detox and
abstinence-based approaches as alternatives for a subset
of prescription-opioid dependent patients. Here, we
argue against the position that OMT capacity has ex-
panded beyond need; and we believe that significant
need still exists, especially in Northern and rural regions
of the province [9, 13].* Correspondence: dmarsh@nosm.ca
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For the majority of opioid-dependent patients, the
evidence overwhelmingly supports OMT [4, 6, 16], and
tapering strategies using methadone or buprenorphine
have a very low probability of resulting in long term
abstinence for opioid-dependent patients [18, 23]. In
fact, we have previously shown that most patients who
attempt to taper off methadone relapse within 12 months
[19]. Fundamentally, the neurology of opioid-
dependence is similar between heroin and other pre-
scription opioids, and it is not comparable to other
substance use disorders due to the profound neural re-
wiring which occurs following prolonged opioid use
[25]. The literature strongly supports OMT for opioid-
dependence treatment of heroin and/or prescription
opioid-dependence [16, 17]. Thus, OMT remains the
clinical strategy with the best evidence for long term
patient safety, social stabilization, and long-term health
benefit – it is for this reason that both methadone and
buprenorphine are recognized by the World Health
Organization as essential medicines [24]. We are not
arguing that methadone and/or buprenorphine are
perfect, but for the majority of patients seeking treat-
ment with the hope of stabilizing the impact dependence
has had on their quality of life, OMT is the best option.
In fact, a recent review of studies on OMT has shown
this approach is even more effective for those using PO
than for heroin users [15].
As suggested by Fisher et al., (2016), alternate
approaches including tapering, counselling and psycho-
social interventions may also have benefit; but again the
evidence suggest that on their own, these treatment
strategies are not as effective as OMT [1, 2]. With
respect to programs which offer a combination of medi-
cation and counselling, evidence suggests that outcomes
are not much better than OMT alone [1, 3, 21]. Other
reports find some patients may benefit from coordin-
ation of OMT and psychosocial supports, but as Fisher
et al., (2016) highlight, more research is needed to know
which patients will benefit from more integrated treat-
ment strategies [8]. Although a combination of psycho-
social interventions and OMT may be as effective as
OMT alone, Amato et al. [1] argue that provision of
OMT should not be abandoned in the absence of
resources for additional psycho-social treatment.
Quantifying the absolute need of OMT is challenging.
However, reliable surrogates such as overdose-related
deaths, overdose-related hospitalizations, and general-
ized opioid prescribing are all reasonable markers which
support the burden and need for opioid-dependence
treatment. Across North America there is an acknowl-
edged need to expand methadone (and/or buprenor-
phine) programming [22]. Fisher et al., (2016) argue that
Ontario’s methadone capacity exceeds that of the United
States; yet, Norah Volkow, the Director of the National
Institute for Drug Abuse in the US recently stated that
expanding access to medication assisted treatment is a
critical part of strategy to deal with the epidemic of
prescription-opioid overdose in a recent article in NEJM
[25]. Thus, comparing Ontario to the US does not seem
a fair comparison.
In an earlier paper calling for expansion of MMT in
Ontario, Fischer and colleagues used European countries
and Australia, rather than the US, as a standard that
would set the target for treatment availability in Ontario;
a goal which is at least two-fold higher than the US
comparison in the current paper [10]. Fisher et. al.,
(2016) also argue that the levels of OMT provision are
disproportionate to other regions in Canada; however,
British Columbia, Saskatchewan, and New Brunswick
have a comparable proportion and patients receiving
OMT (2015 public data).
Several factors limit our collective ability to expand
methadone programming due to the resource intensive
nature of observed dosing treatment. Perhaps the largest
barrier to expansion is the availability of methadone
trained addiction specialists. Recent advances in tele-
medicine have disrupted the most cumbersome barrier
to expansion by allowing a given physician to service a
number of specialized clinics in a broad geographic area
both urban and rural via telemedicine; and Ontario is at
the forefront of telemedicine-delivered OMT. We be-
lieve this a trend that will be adopted by other provinces
and countries in the near future.
In the face of continued increases in opioid overdose
deaths and other negative consequences of untreated
opioid-dependence, OMT is still expanding in Ontario
(and Canada); yet, there are still long wait lists and
patients having to travel over 100 km to the nearest
clinic in rural regions of the province [9]. Like most is-
sues in medicine, we encourage policy makers, payers,
and providers to use a comprehensive assessment of evi-
dence across urban, rural, and remote geographies to
inform measures which may disproportionately disad-
vantage patients who are already marginalized by geo-
graphic, political, and structural factors beyond their
control.
Conclusions
We support the Fisher et. al., (2016) recommendation
that there is a need for more high quality epidemio-
logical surveillance data to quantify and inform resource
allocation towards treatment of opioid-dependence.
However, we strongly oppose the implication that OMT
programming is sufficiently serviced in the province of
Ontario, especially in northern and rural regions. More-
over, the absence of robust data, which Fisher et. al.,
(2016) assert is lacking for other treatment options, is
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not a reason to reduce the availability of our most effect-
ive treatment at a time when people are dying from a
public health crisis. It is our opinion that more resources
should be allocated towards understanding and develop-
ing comprehensive care models which improve the over-
all health outcomes of this complex patient population -
including expanded opioid maintenance treatment
programming, especially in rural and remote regions of
the country.
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